Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and License Agreements and Government Contract (Details)

v3.21.2
Sponsored Research and License Agreements and Government Contract (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2021
Jan. 31, 2021
Feb. 29, 2020
Jan. 31, 2020
Dec. 31, 2019
Oct. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2019
Dec. 31, 2020
Collaborations                                  
Upfront payment received                           $ 125,000,000.0      
Accretion expense                 $ 836,000         1,900,000      
Accounts receivable                 14,991,000         14,991,000     $ 15,973,000
License agreement with unrelated third party                                  
Collaborations                                  
Proceeds from License Fees Received $ 4,000,000.0                                
One-time fee received from license rights granted $ 4,000,000.0                                
Revenue recognized                   $ 4,000,000              
Specified Development Events                                  
Collaborations                                  
Contingent payments                           309,500,000      
Specified Regulatory Events                                  
Collaborations                                  
Contingent payments                           303,100,000      
Specified Product Launch Events                                  
Collaborations                                  
Contingent payments                           816,000,000.0      
Development and regulatory milestones by non-CNS disease products                                  
Collaborations                                  
Contingent payments                           330,000,000.0      
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                                  
Collaborations                                  
Contingent payments                           100,000,000.0      
Development and regulatory milestones by CNS disease products                                  
Collaborations                                  
Contingent payments                           255,000,000.0      
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                                  
Collaborations                                  
Contingent payments                           150,000,000.0      
Maximum                                  
Collaborations                                  
Contingent payments                           1,400,000,000      
Grifols                                  
Collaborations                                  
Upfront payment received             $ 30,000,000.0                    
Contingent payments                           277,500,000      
Revenue recognized                     $ 0            
Revenue, cumulative catch-up       $ 25,000,000.0                          
Deferred revenue                 1,000,000.0         1,000,000.0     1,600,000
Revenue, remaining performance obligation                                 $ 5,000,000.0
Grifols | Licensed Rights                                  
Collaborations                                  
Revenue recognized                       $ 39,900,000          
Grifols | Research Services                                  
Collaborations                                  
Revenue recognized                         $ 3,600,000        
Grifols | One-time delivery of drug supply for commercialization                                  
Collaborations                                  
Revenue recognized                             $ 651,000    
Grifols | Commercial Milestones                                  
Collaborations                                  
Contingent payments             $ 297,500,000                    
Revenue recognized                   1,000,000.0              
Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                                  
Collaborations                                  
Revenue, cumulative catch-up       $ 20,000,000.0                          
Kissei                                  
Collaborations                                  
Upfront payment received               $ 33,000,000.0                  
Contingent payments               $ 147,000,000.0                  
Revenue recognized                             0    
Deferred revenue                 1,400,000         1,400,000      
Revenue, remaining performance obligation                 33,000,000.0         33,000,000.0      
Lilly                                  
Collaborations                                  
Deferred revenue                 744,000         744,000      
Daiichi | Collaborative arrangement                                  
Collaborations                                  
Revenue recognized                 1,800,000   2,100,000     1,800,000 2,100,000    
fostamatinib                                  
Collaborations                                  
Government contract   $ 16,500,000                              
Revenue recognized                 1,000,000.0         9,500,000      
Remaining amount of government award expected to be received in succeeding periods                           7,000,000.0      
fostamatinib | Grifols                                  
Collaborations                                  
Collaborative payment received     $ 20,000,000.0                            
Markup percentage         30.00%                        
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                                  
Collaborations                                  
Contingent payments     17,500,000                            
fostamatinib | Grifols | Creditable advance royalty payment                                  
Collaborations                                  
Collaborative payment received     $ 2,500,000                            
fostamatinib | Grifols | Maximum                                  
Collaborations                                  
Royalty payment as a percentage of net sales                               30.00%  
fostamatinib | Medison Pharma | Financing arrangement                                  
Collaborations                                  
Upfront payment received           $ 5,000,000.0                      
Accrued interest                 50,000   $ 0     387,000 $ 0    
Financing liability with accreted interest expense                 5,500,000         5,500,000      
fostamatinib | Medison Pharma | Commercial and license agreements                                  
Collaborations                                  
Upfront payment received           $ 5,000,000.0                      
Revenue recognized                 75,000         $ 75,000      
R552                                  
Collaborations                                  
Company's percentage of development costs                           20.00%      
Financing component liability                 57,900,000         $ 57,900,000      
Financing liability interest accretion discount rate                           6.40%      
Financing liability with accreted interest expense                 59,800,000         $ 59,800,000      
Revenue, remaining performance obligation                 67,100,000         67,100,000      
R552 | Maximum                                  
Collaborations                                  
Funding commitment                 65,000,000.0         65,000,000.0      
Non-CNS penetrant IP                                  
Collaborations                                  
Revenue recognized                   60,400,000              
Non-CNS penetrant IP | Licensed Rights                                  
Collaborations                                  
Revenue, remaining performance obligation                   $ 6,700,000              
CNS penetrant IP                                  
Collaborations                                  
Revenue recognized                 2,400,000         6,000,000.0      
Research and development services | Grifols                                  
Collaborations                                  
Revenue recognized                 $ 225,000         $ 605,000